(ARDT) Ardent Health Partners - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock •
ARDT: Hospitals, Clinics, Healthcare, Rehabilitation, Surgery
Ardent Health Partners, Inc. is a prominent healthcare services provider in the United States, operating a diverse network of hospitals and clinics that cater to a wide range of medical needs. The company's portfolio includes acute care hospitals, which provide immediate, short-term treatment for severe injuries or episodes of illness, as well as rehabilitation hospitals that offer specialized care and therapy to patients recovering from illness, injury, or surgery. Additionally, Ardent Health Partners operates surgical hospitals, which focus on providing high-quality, patient-centered surgical care. By offering these various types of healthcare facilities, the company aims to deliver comprehensive, patient-focused care to the communities it serves.
With its roots dating back to 2001, Ardent Health Partners, Inc. has established itself as a significant player in the US healthcare landscape. Headquartered in Brentwood, Tennessee, the company has developed a strong presence in the healthcare industry, driven by its commitment to quality, innovation, and patient satisfaction. As a subsidiary of EGI-AM Investments, L.L.C., Ardent Health Partners benefits from the resources and expertise of its parent company, enabling it to stay at the forefront of healthcare services and respond to the evolving needs of its patients and the broader healthcare market.
From a financial perspective, Ardent Health Partners, Inc. is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol ARDT. Its common stock is classified under the GICS Sub Industry category of Health Care Facilities, which encompasses companies that operate hospitals, nursing homes, and other healthcare facilities. For more information about Ardent Health Partners, Inc., including its services, mission, and values, investors and stakeholders can visit the company's website at https://www.ardenthealth.com, which provides a wealth of information on its operations, leadership, and commitment to delivering exceptional healthcare services.
Additional Sources for ARDT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ARDT Stock Overview
Market Cap in USD | 2,591m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 2024-07-18 |
ARDT Stock Ratings
Growth 5y | -49.8% |
Fundamental | 25.9% |
Dividend | - |
Rel. Strength Industry | -393 |
Analysts | 4.4/5 |
Fair Price Momentum | 12.88 USD |
Fair Price DCF | 17.55 USD |
ARDT Dividends
No Dividends PaidARDT Growth Ratios
Growth Correlation 3m | -71.4% |
Growth Correlation 12m | -40.8% |
Growth Correlation 5y | -40.8% |
CAGR 5y | -11.52% |
CAGR/Mean DD 5y | -1.01 |
Sharpe Ratio 12m | -0.26 |
Alpha | -15.39 |
Beta | -0.02 |
Volatility | 66.07% |
Current Volume | 841.7k |
Average Volume 20d | 302.9k |
As of January 22, 2025, the stock is trading at USD 14.21 with a total of 841,745 shares traded.
Over the past week, the price has changed by +1.14%, over one month by -10.63%, over three months by -23.85% and over the past year by -11.52%.
Neither. Based on ValueRay Fundamental Analyses, Ardent Health Partners is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.86 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARDT as of January 2025 is 12.88. This means that ARDT is currently overvalued and has a potential downside of -9.36%.
Ardent Health Partners has received a consensus analysts rating of 4.40. Therefor, it is recommend to buy ARDT.
- Strong Buy: 6
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ARDT Ardent Health Partners will be worth about 13.9 in January 2026. The stock is currently trading at 14.21. This means that the stock has a potential downside of -2.11%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 22.8 | 60.3% |
Analysts Target Price | 22.8 | 60.3% |
ValueRay Target Price | 13.9 | -2.1% |